Merck KGaA
XETRA:MRK

Watchlist Manager
Merck KGaA Logo
Merck KGaA
XETRA:MRK
Watchlist
Price: 141.75 EUR 2.49% Market Closed
Market Cap: 61.6B EUR
Have any thoughts about
Merck KGaA?
Write Note

Merck KGaA
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Merck KGaA
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Merck KGaA
XETRA:MRK
Pre-Tax Income
€3.4B
CAGR 3-Years
-1%
CAGR 5-Years
17%
CAGR 10-Years
9%
ATAI Life Sciences NV
NASDAQ:ATAI
Pre-Tax Income
-$39.3m
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bayer AG
XETRA:BAYN
Pre-Tax Income
-€209m
CAGR 3-Years
N/A
CAGR 5-Years
37%
CAGR 10-Years
N/A
MPH Health Care AG
XETRA:93M1
Pre-Tax Income
€29.8m
CAGR 3-Years
N/A
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Dermapharm Holding SE
XETRA:DMP
Pre-Tax Income
€141.8m
CAGR 3-Years
-14%
CAGR 5-Years
6%
CAGR 10-Years
N/A
PharmaSGP Holding SE
XETRA:PSG
Pre-Tax Income
€21.9m
CAGR 3-Years
16%
CAGR 5-Years
2%
CAGR 10-Years
N/A
No Stocks Found

Merck KGaA
Glance View

Market Cap
61.6B EUR
Industry
Pharmaceuticals

Merck KGaA, a global science and technology company based in Darmstadt, Germany, has carved out a distinctive niche in the life sciences, healthcare, and high-performance materials sectors. With a rich history tracing back to 1668, it stands as one of the oldest pharmaceutical and chemical companies in the world. Merck KGaA operates in three primary business segments: Healthcare, Life Science, and Performance Materials. The Healthcare division focuses on innovative prescription medicines and therapies, while the Life Science segment provides essential tools and services for research and production in the life sciences. Meanwhile, the Performance Materials branch offers state-of-the-art solutions for electronic applications and displays. This diverse portfolio positions Merck KGaA as a critical player in industries that are fundamental to advancements in health and technology. Investors should note that Merck KGaA has made strategic investments in research and development, committing approximately 15% of its annual revenue to this area, underscoring its dedication to innovation and growth. The company boasts a solid financial position, with a revenue forecast expected to rise steadily, driven by a robust pipeline of patented drugs and growing global demand for biopharmaceuticals. With a focus on sustainability and digital transformation, Merck KGaA is not only prepared to thrive in today’s competitive landscape but is also positioning itself for long-term success. By blending a legacy of scientific excellence with contemporary challenges, Merck KGaA represents an intriguing opportunity for investors seeking to navigate the dynamic health and technology markets.

MRK Intrinsic Value
157.06 EUR
Undervaluation 10%
Intrinsic Value
Price

See Also

What is Merck KGaA's Pre-Tax Income?
Pre-Tax Income
3.4B EUR

Based on the financial report for Sep 30, 2024, Merck KGaA's Pre-Tax Income amounts to 3.4B EUR.

What is Merck KGaA's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
9%

Over the last year, the Pre-Tax Income growth was -9%. The average annual Pre-Tax Income growth rates for Merck KGaA have been -1% over the past three years , 17% over the past five years , and 9% over the past ten years .

Back to Top